CITI PHARMA LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.38 PKR | -3.33% |
|
+7.19% | +11.12% |
| Sales 2022 | 9.78B 35.11M 2.8B | Sales 2023 | 12.4B 44.51M 3.55B | Capitalization | 4.88B 17.5M 1.4B |
|---|---|---|---|---|---|
| Net income 2022 | 636M 2.28M 182M | Net income 2023 | 658M 2.36M 188M | EV / Sales 2022 | 0.65 x |
| Net cash position 2022 | 1.05B 3.79M 302M | Net Debt 2023 | 262M 941K 75.09M | EV / Sales 2023 | 0.41 x |
| P/E ratio 2022 |
11.7
x | P/E ratio 2023 |
7.41
x | Employees | 594 |
| Yield 2022 * |
-
| Yield 2023 |
11.7% | Free-Float | 45.19% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.33% | ||
| 1 week | +7.19% | ||
| Current month | +13.76% | ||
| 1 month | +13.76% | ||
| 3 months | +20.90% | ||
| 6 months | +14.75% | ||
| Current year | +11.12% |
1 week
24.11
27.88
1 month
23.0027.88
Current year
20.0127.88
1 year
19.0728.35
3 years
19.0750.05
5 years
19.0750.05
10 years
19.0750.05
| Managers | Title | Age | Since |
|---|---|---|---|
Rizwan Ahmad
CEO | Chief Executive Officer | - | 07/10/12 |
Asif Iqbal
DFI | Director of Finance/CFO | - | 31/10/19 |
| Director/Board Member | - | 12/10/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | - | |
Nadeem Amjad
CHM | Chairman | - | 07/10/12 |
Rizwan Ahmad
CEO | Chief Executive Officer | - | 07/10/12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 26.38 | -3.33% | 3,049,061 |
| 29/04/24 | 27.29 | +3.65% | 6,006,637 |
| 26/04/24 | 26.33 | +5.11% | 7,668,526 |
| 25/04/24 | 25.05 | +2.41% | 2,881,181 |
| 24/04/24 | 24.46 | +0.33% | 564,089 |
End-of-day quote Pakistan S.E., April 29, 2024
More quotes
Citi Pharma Limited is a Pakistan-based pharmaceutical company. The principal activity of the Company is manufacturing and sale of pharmaceuticals, medical chemicals, and botanical products. The Company's departments include API, formulation, and research and development. Its key products under the API segment include Paracetamol, Amoxicillin, Levofloxacin, Cefixime, Ciprofloxacin, Cephradine, Norfloxacin, Aspirin, Ibuprofen, and Ascorbic acid. The Company's formulation department produces tablets, liquids, and capsules. Its research and development activities deal with various forms ranging from the development of new chemical/drug entities to the evaluation of existing products for alternative indications. Its other products include Amlodopine, Nimesulide, Mefenamic Acid, Simvastatin, Ranitiddine as Hcl, and Levofloxicen(as Hemihydrate), among others.
Sector
Pharmaceuticals
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +11.12% | 21.66M | |
| +33.25% | 699B | |
| +28.59% | 571B | |
| -3.55% | 364B | |
| +18.16% | 326B | |
| +4.36% | 286B | |
| +14.81% | 236B | |
| +4.93% | 198B | |
| -9.78% | 194B | |
| -3.69% | 149B |
- Stock Market
- Equities
- CPHL Stock
